OptiBiotix Health PLC (GB:OPTI)
LSE:OPTI
Want to see GB:OPTI full AI Analyst Report?
Top Page
OptiBiotix Health
(LSE:OPTI)
Select Model
Select Model
Rating:49Neutral
Price Target:
6.00 p
▼(-11.11% Downside)
Action:Reiterated
Date:05/30/26
The score is held back primarily by weak financial performance—ongoing losses and cash burn despite strong revenue growth and better gross margins. Technicals are supportive in the near term (positive MACD and trading above short-term averages) but are tempered by overbought RSI/Stoch readings. Valuation remains constrained by unprofitability and the absence of a dividend yield.
Positive Factors
Strong recent revenue growth
A ~130% jump in 2025 revenue indicates accelerating commercial traction and partner adoption of its microbiome ingredients. Durable revenue expansion from licensing and ingredient supply can create a larger recurring royalty base and support scaling of fixed R&D and SG&A over coming quarters.
Negative Factors
Persistent negative operating cash flow
Consistent negative operating cash flow (~-£1.77m in 2025) signals ongoing cash burn to fund operations and commercialization. Over months, this structural cash gap raises reliance on external financing, increasing dilution or covenant risk unless the company achieves sustained positive cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong recent revenue growth
A ~130% jump in 2025 revenue indicates accelerating commercial traction and partner adoption of its microbiome ingredients. Durable revenue expansion from licensing and ingredient supply can create a larger recurring royalty base and support scaling of fixed R&D and SG&A over coming quarters.
Read all positive factors
OptiBiotix Health (OPTI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£6.15M
Dividend YieldN/A
Average Volume (3M)268.80K
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth34.02%
EPS Growth-93.85%
CountryUK
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding103,300,300
10 Day Avg. Volume266,472
30 Day Avg. Volume268,800
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)5.86
P/FCF Ratio-3.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OptiBiotix Health Business Overview & Revenue Model
Company Description
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, a...
How the Company Makes Money
OptiBiotix primarily makes money by commercialising its microbiome-related intellectual property through business-to-business agreements rather than operating as a large direct-to-consumer brand. The main revenue streams are: (1) Licensing and com...
OptiBiotix Health Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17M | 870.00K | 644.00K | 457.00K | 2.21M |
| Gross Profit | 614.00K | 331.00K | 320.00K | 244.00K | 1.12M |
| EBITDA | -2.93M | -2.06M | -1.84M | 2.75M | 6.51M |
| Net Income | -3.89M | -1.80M | -2.04M | 2.59M | 6.26M |
Balance Sheet | |||||
| Total Assets | 6.89M | 9.04M | 9.40M | 11.55M | 20.14M |
| Cash, Cash Equivalents and Short-Term Investments | 1.04M | 739.00K | 635.00K | 1.05M | 2.01M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 819.36K |
| Total Liabilities | 610.00K | 647.00K | 532.00K | 643.00K | 1.97M |
| Stockholders Equity | 6.28M | 8.40M | 8.87M | 10.90M | 18.14M |
Cash Flow | |||||
| Free Cash Flow | -1.77M | -1.77M | -1.53M | -1.28M | -1.76M |
| Operating Cash Flow | -1.77M | -1.77M | -1.53M | -1.11M | -1.56M |
| Investing Cash Flow | 1.35M | 587.00K | 1.11M | -331.00K | -193.51K |
| Financing Cash Flow | 713.00K | 1.28M | 0.00 | 485.00K | 2.90M |
OptiBiotix Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £5.05M | -2.51 | -53.79% | ― | ― | 85.56% | |
49 Neutral | £6.15M | -1.58 | -2.42% | ― | 34.02% | -93.85% | |
47 Neutral | £12.11M | -34.94 | -433.59% | ― | ― | 69.64% | |
47 Neutral | £28.51M | -62.37 | -10.01% | ― | 95.16% | 85.60% | |
44 Neutral | £4.40M | -3.58 | -153.80% | ― | ― | 93.02% | |
41 Neutral | £3.14M | -0.34 | -115.97% | ― | -87.82% | -746.51% |
* Healthcare Sector Average
GB:OPTI
OptiBiotix Health
5.95
-6.05
-50.42%
GB:TCF
Evgen Pharma
0.24
-0.03
-9.62%
GB:FUM
Futura Medical
0.54
-8.11
-93.76%
GB:NFX
Nuformix Plc
0.17
0.07
76.84%
GB:CIZ
Cizzle Biotechnology Holdings PLC
2.85
1.15
67.65%
GB:SBTX
SkinBioTherapeutics
11.00
-5.63
-33.83%
OptiBiotix Health Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
OptiBiotix Finance Director Increases Stake With Share Purchase
Positive
May 29, 2026
OptiBiotix Health plc reported that finance director David Blain has increased his stake in the company by purchasing 158,965 ordinary shares at 6.17 pence each on 28 May 2026. Following the transaction, Blain now holds 243,018 shares, representin...
Business Operations and StrategyFinancial Disclosures
OptiBiotix lifts revenues and margins as it pivots to profitability and tighter cost control
Positive
May 28, 2026
OptiBiotix Health reported strong trading for 2025, with revenue up 34% to £1.17m, gross profit rising 85% to £614k and margins improving to 53%, supported by growing international sales that now account for 73% of turnover, particularly...
Business Operations and StrategyProduct-Related Announcements
OptiBiotix to Showcase Enhanced SweetBiotix Sugar Substitute at London Investor Event
Positive
May 14, 2026
OptiBiotix Health plans to showcase its SweetBiotix sugar-substitute fibres to shareholders at a sampling event in London in June 2026, following a reported manufacturing breakthrough that delivers higher yields, purer and better-tasting product, ...
Business Operations and StrategyPrivate Placements and Financing
OptiBiotix boosts cash runway with partial sale of SkinBioTherapeutics stake
Positive
May 1, 2026
OptiBiotix Health has sold 7.5 million shares in SkinBioTherapeutics, raising £675,000 in cash that will be applied to general working capital and is expected to extend the company’s funding runway into the first half of 2027. Following...
Business Operations and StrategyFinancial Disclosures
OptiBiotix Delivers Strong Growth and Tightens Focus on Profitability
Positive
Apr 1, 2026
OptiBiotix Health reported a strong 2025 performance, with revenue up 30% to £1.13m, gross profit up 82% to £603,000 and margins rising to 53%, supported by stable operating costs and a cash balance of £1.03m. The company’s as...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.